Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Intravitreal Ziv-Aflibercept in Patients With Diabetic Macular Edema Refractory to Intravitreal Bevacizumab Publisher Pubmed



Ebrahimiadib N1 ; Lashay A1 ; Riaziesfahani H1 ; Jamali S1 ; Khodabandeh A1 ; Zarei M1 ; Roohipoor R1 ; Khojasteh H1 ; Bazvand F1 ; Ojani M1 ; Shahabinejad M1 ; Modjtahedi BS2, 3 ; Davoudi S4 ; Riaziesfahani M5
Authors

Source: Ophthalmic Surgery Lasers and Imaging Retina Published:2020


Abstract

BACKGROUND AND OBJECTIVE: To evaluate the efficacy of intravitreal ziv-aflibercept (IVZ) in patients with diabetic macular edema (DME) resistant to intravitreal bevacizumab (IVB). PATIENTS AND METHODS: This prospective study was conducted in patients with persistent DME. Patients were switched to IVZ no longer than 6 weeks after the last three consecutive monthly IVB treatments and monitored over a course of 12 weeks. Changes in best-corrected visual acuity (BCVA), central macular thickness (CMT), and macular volume on optical coherence tomography were compared. RESULTS: A total of 59 eyes (38 patients) were included. Mean BCVA improved from 0.84 to 0.71 logMAR (P = .001) after first IVZ treatment and remained significant. In a subgroup analysis, this significance was observed only in the group with baseline visual acuity of less than 20/50. Mean CMT decreased from 479 μm to 364 μm (P = .004) after the first IVZ injections and remained significant. CONCLUSION: IVZ may be best reserved for patients with persistent DME after initial failure with bevacizumab, with less likelihood for anatomic or functional improvement in those with mild persistent DME. Copyright © 2020 Slack Incorporated. All rights reserved.
Other Related Docs
14. Intraocular Injection of Stivant® (A Biosimilar to Bevacizumab): A Case Series, Journal of Ophthalmic and Vision Research (2021)